Perrigo Company plc Announces Strategic Organizational Update to Drive Sustainable Growth Aligned with SDGs

Introduction

Dublin, July 1, 2025 – Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, has announced a strategic organizational update to scale and optimize its global category-led, market activation growth model. This initiative aims to enhance agility, accelerate innovation, and drive long-term sustainable growth, in alignment with the United Nations Sustainable Development Goals (SDGs), particularly SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation, and Infrastructure), and SDG 12 (Responsible Consumption and Production).

Strategic Alignment and Sustainable Development Goals

The organizational realignment supports Perrigo’s multi-year Stabilize, Streamline and Strengthen (‘Three-S’) plan, emphasizing operational readiness and sustainability. This approach contributes to:

1. SDG 3 – Good Health and Well-being: By expanding access to self-care products that improve health outcomes without prescriptions, Perrigo enhances consumer health globally.
2. SDG 9 – Industry, Innovation, and Infrastructure: Accelerating innovation through streamlined category leadership and market activation fosters resilient infrastructure and sustainable industrialization.
3. SDG 12 – Responsible Consumption and Production: Optimizing product portfolios and market strategies promotes sustainable consumption patterns and efficient resource use.

Key Highlights of the Category-Led, Market Activation Growth Model

• Streamlining for Long-Term Sustainable Growth: The new alignment enhances speed, agility, and scalability while reducing bureaucracy, enabling Perrigo to serve more consumers across diverse price points sustainably.
• Proven Growth Model: The model has already delivered measurable success in Perrigo’s Consumer Self-Care International (CSCI) and Consumer Self-Care Americas (CSCA) businesses, including accelerated regulatory milestones and digital market activations that support SDG 3 and SDG 9.
• Unlocking Portfolio Potential: Centralizing global brand-building capabilities enables the delivery of consumer-preferred self-care solutions, fostering innovation and efficiency aligned with SDG 12.
• Leadership Alignment for Execution Excellence: Roberto Khoury has been appointed EVP and Chief Commercial Officer to lead global market activation, ensuring cohesive execution of category strategies and commercial functions worldwide.
• Financial Guidance: The organizational update does not impact Perrigo’s full-year 2025 adjusted EPS guidance or reporting segments, ensuring financial stability during transformation.

Leadership Changes and Acknowledgments

• The roles of EVP and President of CSCI and CSCA will be discontinued.
• Triona Schmelter, EVP and President CSCA, will depart the organization by October 31, 2025, after significant contributions including the launch of Opill®, a milestone in women’s reproductive health supporting SDG 3.
• Perrigo expresses gratitude for Ms. Schmelter’s leadership in navigating complex markets and strengthening store brand positions.

Implementation and Compliance

The organizational alignment will follow all applicable legal information and consultation processes and is expected to be implemented over the coming months, ensuring responsible corporate governance aligned with SDG 16 (Peace, Justice, and Strong Institutions).

About Perrigo

Perrigo Company plc is a pure-play self-care company with over 100 years of experience providing high-quality health and wellness solutions primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers accessible and trusted products that empower consumers to manage their health independently, advancing SDG 3.

The company’s business model leverages cash-generative store brand private label offerings to invest in leading brands such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®, promoting innovation and sustainable consumption.

For more information, visit www.perrigo.com.

Forward-Looking Statements

This report contains forward-looking statements subject to risks and uncertainties that may cause actual results to differ materially. Investors are encouraged to review Perrigo’s filings with the U.S. Securities and Exchange Commission for detailed risk factors and financial information, supporting transparency and accountability consistent with SDG 16.

Contact Information

• Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications, Phone: (269) 686-3373, Email: [email protected]
• Nicholas Gallagher, Senior Manager, Global Investor Relations & Corporate Communications, Phone: (269) 686-3238, Email: [email protected]

1. Sustainable Development Goals (SDGs) Addressed or Connected

1. SDG 3: Good Health and Well-being
   • The article discusses Perrigo’s focus on consumer self-care products, which contribute to health and well-being by providing accessible over-the-counter (OTC) health solutions.
   • Launch of products like Opill® related to women’s reproductive health.
2. SDG 9: Industry, Innovation and Infrastructure
   • The article highlights Perrigo’s efforts to accelerate innovation, streamline operations, and optimize growth models, reflecting industrial innovation and infrastructure improvements.
3. SDG 8: Decent Work and Economic Growth
   • Organizational alignment to enhance agility and performance supports sustainable economic growth and improved productivity.
4. SDG 12: Responsible Consumption and Production
   • Focus on efficient portfolio management and scaling molecules more efficiently suggests sustainable production and consumption patterns.

2. Specific Targets Under Those SDGs Identified

1. SDG 3: Good Health and Well-being
   • Target 3.8: Achieve universal health coverage, including access to quality essential health-care services and access to safe, effective, quality, and affordable essential medicines and vaccines.
   • Target 3.7: Ensure universal access to sexual and reproductive health-care services.
2. SDG 9: Industry, Innovation and Infrastructure
   • Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors, and encourage innovation.
3. SDG 8: Decent Work and Economic Growth
   • Target 8.2: Achieve higher levels of economic productivity through diversification, technological upgrading, and innovation.
4. SDG 12: Responsible Consumption and Production
   • Target 12.2: Achieve the sustainable management and efficient use of natural resources.

3. Indicators Mentioned or Implied to Measure Progress

1. SDG 3 Indicators
   • Proportion of population with access to affordable essential medicines and health products (implied by Perrigo’s OTC product accessibility).
   • Coverage of reproductive health services (implied through the launch and impact of Opill®).
2. SDG 9 Indicators
   • Research and development expenditure as a proportion of GDP (implied by Perrigo’s focus on accelerating innovation and digital activations).
   • Number of new products developed or regulatory milestones achieved (mentioned as accelerated regulatory milestones).
3. SDG 8 Indicators
   • Growth rate of real GDP per employed person (implied by organizational alignment to drive performance and growth).
   • Productivity measures related to operational efficiency and market activation.
4. SDG 12 Indicators
   • Material footprint, material footprint per capita, and per GDP (implied through efficient scaling and portfolio management).
   • Percentage of companies publishing sustainability reports (implied by Perrigo’s transparency and strategic communication).

4. Table of SDGs, Targets, and Indicators

Source: prnewswire.com